©The Author(s) 2026.
World J Clin Oncol. Jan 24, 2026; 17(1): 114012
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.114012
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.114012
Table 1 Baseline characteristics between survivors and non-survivors, n (%)
| Variable | Total (n = 1142) | Survivors (n = 615) | Non-survivors (n = 527) | Statistic | P value |
| Gender | |||||
| Male | 783 (68.56) | 407 (66.18) | 376 (71.35) | ||
| Female | 359 (31.44) | 208 (33.82) | 151 (28.65) | ||
| Age (years) | |||||
| ≤ 29 | 47 (4.12) | 36 (76.60) | 11 (23.40) | ||
| 30-39 | 202 (17.69) | 132 (65.35) | 70 (34.65) | ||
| 40-49 | 522 (45.70) | 268 (51.34) | 254 (48.66) | ||
| 50-59 | 279 (24.43) | 138 (49.46) | 141 (50.54) | ||
| 60-69 | 88 (7.71) | 41 (46.59) | 47 (53.41) | ||
| ≥ 70 | 4 (0.35) | 0 (0) | 4 (100) | ||
| Tumor stage (%) | χ² = 6.08 | 0.193 | |||
| I | 0.47 | 0.73 | 0.23 | ||
| II | 5.44 | 7.07 | 3.90 | ||
| III | 54.61 | 56.65 | 52.44 | ||
| IVa | 35.46 | 34.86 | 36.10 | ||
| IVb | 4.02 | 3.66 | 4.36 | ||
| TAM (U/mL) | 89.27 ± 12.43 | 87.73 ± 11.09 | 90.89 ± 13.60 | t = 1.42 | 0.159 |
| TSGF (U/mL) | 54.40 ± 17.22 | 54.37 ± 17.19 | 54.43 ± 17.28 | t = 0.05 | 0.959 |
| NSE (ng/mL) | 2.61 ± 1.95 | 2.55 ± 2.11 | 2.68 ± 1.79 | t = 0.61 | 0.539 |
| CEA (mg/L) | 1.41 ± 1.48 | 1.22 ± 0.95 | 1.58 ± 1.83 | t = 2.36 | 0.019 |
| Feritin (ng/mL) | 133.42 ± 76.11 | 97.32 ± 68.38 | 167.22 ± 67.04 | t = 9.84 | < 0.001 |
| AFP (ng/mL) | 1.73 ± 2.09 | 1.65 ± 2.12 | 1.82 ± 2.05 | t = 0.77 | 0.444 |
| AST (U/L) | 23.45 ± 16.30 | 23.58 ± 17.14 | 23.30 ± 15.35 | t = -0.26 | 0.798 |
| ALT (U/L) | 26.83 ± 29.59 | 27.39 ± 29.30 | 26.22 ± 29.93 | t = -0.60 | 0.547 |
| ALP (U/L) | 75.67 ± 27.43 | 75.33 ± 28.26 | 76.04 ± 26.52 | t = 0.38 | 0.706 |
| LDH (U/L) | 172.59 ± 42.86 | 169.30 ± 42.23 | 176.27 ± 43.32 | t = 2.36 | 0.018 |
| GGT (U/L) | 33.87 ± 53.87 | 31.13 ± 27.63 | 36.90 ± 72.44 | t = 1.55 | 0.122 |
| 5-NT (U/L) | 6.07 ± 5.51 | 5.91 ± 5.14 | 6.25 ± 5.89 | t = 0.89 | 0.371 |
| GPDA (U/L) | 67.91 ± 21.38 | 68.18 ± 20.06 | 67.61 ± 22.76 | t = -0.38 | 0.704 |
| ADA (U/L) | 15.18 ± 23.80 | 14.58 ± 17.97 | 15.83 ± 28.91 | t = 0.75 | 0.450 |
| MAO (U/L) | 4.77 ± 2.37 | 4.75 ± 2.33 | 4.80 ± 2.41 | t = 0.26 | 0.794 |
- Citation: Tang Q, Wu Y, Chen L, Jia QY, Tang FQ. Ferritin as a novel predictive index for nasopharyngeal carcinoma survival and therapeutic efficacy of different chemotherapy regimens. World J Clin Oncol 2026; 17(1): 114012
- URL: https://www.wjgnet.com/2218-4333/full/v17/i1/114012.htm
- DOI: https://dx.doi.org/10.5306/wjco.v17.i1.114012